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Abstract
Background: In recent years an increasing number of public investments and policy changes have been made to
improve the availability, affordability and quality of medicines available to consumers in developing countries,
including anti-malarials. It is important to monitor the extent to which these interventions are successful in
achieving their aims using quantitative data on the supply side of the market. There are a number of challenges
related to studying supply, including outlet sampling, gaining provider cooperation and collecting accurate data on
medicines. This paper provides guidance on key steps to address these issues when conducting a medicine outlet
survey in a developing country context. While the basic principles of good survey design and implementation are
important for all surveys, there are a set of specific issues that should be considered when conducting a medicine
outlet survey.
Methods: This paper draws on the authors’ experience of designing and implementing outlet surveys, including
the lessons learnt from ACTwatch outlet surveys on anti-malarial retail supply, and other key studies in the field. Key
lessons and points of debate are distilled around the following areas: selecting a sample of outlets; techniques for
collecting and analysing data on medicine availability, price and sales volumes; and methods for ensuring high
quality data in general.
Results and conclusions: The authors first consider the inclusion criteria for outlets, contrasting comprehensive
versus more focused approaches. Methods for developing a reliable sampling frame of outlets are then presented,
including use of existing lists, key informants and an outlet census. Specific issues in the collection of data on
medicine prices and sales volumes are discussed; and approaches for generating comparable price and sales
volume data across products using the adult equivalent treatment dose (AETD) are explored. The paper concludes
with advice on practical considerations, including questionnaire design, field worker training, and data collection.
Survey materials developed by ACTwatch for investigating anti-malarial markets in sub-Saharan Africa and Asia
provide a helpful resource for future studies in this area.
Keywords: Medicine, Retail outlet survey methods, Price, availability, Market share, Health facility survey, Private
sector
Background
The World Health Organization (WHO) defines its
vision for essential medicines as “. . . that people
everywhere have access to the essential medicines
they need; that the medicines are safe, effective, and
of good quality; and prescribed and used rationally”
[1]. In line with this, the Millennium Development
Goals acknowledge the need to improve the availabil-
ity of affordable quality medicines for the world’s
poor [2]. Modern medicines account for 20–60% of
health spending in developing countries and up to
90% of the population in developing countries
purchase medicines through out-of-pocket payments
[1]. The WHO Model List of Essential Medicines
includes, among other classes of medicines, anti-
malarials, anti-bacterial medicines, anti-tuberculosis
medicines, anti-retrovirals, oral rehydration salts,
vaccines, and contraceptives. Effective prevention and
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treatment requires that these essential medicines be
available at affordable prices at all times [2].
In recent years an increasing number of public invest-
ments have been made to improve access to high quality
essential medicines by increasing medicine availability
and reducing price [3]. Interventions include regulatory
measures to ban harmful or expired drugs [4]; policy
changes to promote the use of less expensive generics
over originator brands; updating or establishing national
Essential Medicines Lists to guide public sector procure-
ment and supply; schemes that promote local medicine
production; and increased efforts to work with private
medicines sellers [5,6]. Given the financial investments
and policy maker commitments to increasing access to
essential medicines, it is important to monitor the extent
to which these interventions achieve their aims using
rigorous quantitative data. The impact of these interven-
tions needs to be considered on both the supply of and
demand for essential medicines.
It is generally acknowledged that medicine demand
has been studied in greater detail than medicine supply.
The collection of nationally representative quantitative
demand-side data on a broad range of population health
topics has been conducted since 1984 through the
Demographic and Health Surveys (DHS) and later the
Multiple Indicator Cluster Surveys (MICS). This infor-
mation can be used to answer questions such as where
people seek treatment and how quickly, what type of
treatment they receive, and how good caregiver know-
ledge is on causes and symptoms of illness. Many
resources are publicly available for such surveys, includ-
ing sample questionnaires, guidelines for sampling, field
worker training materials and data analysis plans [7].
A number of quantitative methods are available to
researchers interested in the supply side of the medicine
market. The quality of the provider-client interaction can
be investigated using mystery shoppers, exit interviews,
and observational studies [8]; drug samples can be col-
lected to investigate the prevalence of counterfeit and /or
sub-standard medicines in the market [9]; and medicine
outlet surveys (sometimes called distribution surveys or
retail surveys), can be conducted to collect data on self-
reported practices of providers and availability and price
of medicines. Medicine outlets are defined as providers
that sell/dispense drugs directly to consumers.
However, there are a number of challenges related to
studying the supply side of the market, including outlet
sampling, gaining provider cooperation and collecting ac-
curate data. In many countries, medicine sellers are not
registered and therefore official lists of providers cannot
be used as a reliable sampling frame as they may be out of
date or exclude important types of medicine sellers such
as drug stores, mobile providers or general retailers [10].
Gaining cooperation of providers when information may
be legally or commercially sensitive can result in high
rates of refusal or under-reporting of products they know
to be banned or for which they do not hold a license. Pro-
viders may be reluctant to share their records, fearing the
information may be disclosed to drug registration bodies
or revenue authorities or competitors. Obtaining informa-
tion related to medicine price, availability and sales
volumes is a challenge when multiple brands, formula-
tions and strengths exist. Furthermore, the private com-
mercial sector in many developing countries lacks routine
health information system, including routine information
on stock. Despite (or more likely, because of) the chal-
lenges associated with studying the informal sector, this
area has been highlighted as a priority for further meth-
odological development [8].
This paper provides guidance on addressing these
challenges when conducting a medicine outlet survey in
a developing country context, drawing primarily on pre-
vious experience of studying the anti-malarial market.
While the basic principles of good survey design and im-
plementation are important for all surveys, the paper
highlights a set of specific issues that should be consid-
ered when conducting a medicine outlet survey.
Methods
This paper draws on the authors’ experience of design-
ing and implementing outlet surveys, including the les-
sons learnt from ACTwatch outlet surveys [11] and
other key studies in the field. The authors experience
was primarily with surveys of the market for malaria-
related commodities, but the authors also drew on
examples of broader medicine surveys. The ACTwatch
project investigates markets for anti-malarials and mal-
aria diagnostic testing, and its outlet survey method-
ology has been implemented more than 30 times since
2008 in over 10 developing countries across Africa and
Southeast Asia [11]. Through informal group discussions
the authors reflected on their choice of methods, and
their experiences in the field, in analysis, and in results
dissemination. Key lessons and points of debate are dis-
tilled around the following areas: outlet inclusion criteria
and appropriate sampling methods; techniques for col-
lecting and analysing data on medicine availability, price
and sales volumes; and methods for ensuring high qual-
ity data. Where relevant, reference is made to a suite of
ACTwatch tools that are available online to facilitate fur-
ther studies in this area.
Results
Selecting a sample for a medicine outlet survey
Key study design decisions include selection of outlet types
to include, and choice of methods for locating and select-
ing outlets. The choice of outlet types included in a survey
will depend on the nature of the research question, and the
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study’s aims and objectives. Some studies focus on specific
outlet types, such as licensed pharmacies [12], private not
for profit clinics [13], or public health facilities [14], while
others have a broader remit covering all outlets in the pri-
vate sector [15,16] or across all sectors where a specific
class of medicines may be stocked [17-19]. For example,
ACTwatch included all outlets with the ‘potential’ to sell
anti-malarials, covering public/not for profit and private
sectors, and a broad range of outlet types, from public fa-
cilities, private hospitals and pharmacies to more informal
outlets such as drug stores, kiosks and hawkers [11]. More
focused inclusion criteria may lead to a more logistically
feasible survey, and provide more detailed data on specific
outlet types. However, a comprehensive approach such as
that used by ACTwatch has the benefit of providing data
on the whole market for these medicines, enabling presen-
tation of representative data on all sellers, and calculations
of market share, which can be used to monitor the impact
of interventions over time. It also allows comparisons be-
tween sectors and outlet types. Data on unregistered provi-
ders can also be particularly illuminating for policy makers
in countries with weak regulatory environments and poor
information systems in the private sector.
A variety of methods can be used to develop a sam-
pling frame of outlets. Common approaches include
using pre-existing lists, local key informants, and/or a
census approach. Depending on the research question
one of these methods may be sufficient on its own, how-
ever a combination of methods may be required to en-
sure the most accurate number, and location, of eligible
outlets are identified. Official lists provide an easy way
of estimating the number of providers operating in a
given area by outlet type [12,14]. However, they may be
incomplete or outdated (e g, omitting providers who are
unregistered or awaiting official registration, or including
those whose registration has expired), and generally do
not capture provider types operating without authorization,
which often make up a large share of medicine sellers
[10,15,16]. Privately compiled outlet lists such as those
developed during other research studies or by other private
institutions (e g, IMS health), may include outlets not cap-
tured by official lists [20]. However, such lists may not be
available across all settings, and as with official lists, may
be outdated. This reflects the high turnover in retail out-
lets, especially smaller stalls and kiosks. Moreover, given
the lack of road maps, or unique identifiers for many out-
lets, those listed may be difficult to locate. The feasibility
of using lists developed by other researchers will also de-
pend on whether consent for sharing these data was
obtained at the time of data collection. There may also be
a financial charge for such data if they are held by com-
mercial organizations. The use of lists must, therefore,
generally be complemented by other outlet identification
methods.
Interviews with local key informants (such as people
living and working in the study area, community and vil-
lage leaders and local administrative councils), can be
used to update existing lists of medicine sellers, as well
as helping to define administrative boundaries and iden-
tify the range and location of local outlets selling medi-
cines [12,15,16]. However, such interviews are unlikely
to provide a complete and accurate list of all medicines
sellers, and therefore also require supplementation.
A census involves a team of data collectors moving sys-
tematically through a defined area in order to identify all
eligible outlets [10,15,16]. This is likely to be the most
comprehensive approach to developing a sampling frame
but faces a number of practical implementation challenges.
Interviewers must visit all outlets that may meet the study’s
inclusion criteria. Where this is based on stocking of cer-
tain types of medicines it may be unclear beforehand which
types of outlets this will include, necessitating visits to not
only clinics, pharmacies and drug shops, but also general
stores, market stalls, kiosks etc., which requires significant
time and resources. At times, thousands of outlets may be
visited but only a small percentage will have medicines in
stock. There are also challenges in monitoring the quality
of the census to ensure that interviewers approach all rele-
vant outlets. Finally it is only feasible to use the census ap-
proach in relatively small geographical areas such as wards
or sub-locations.
Once the types of outlet to include in the survey and
method for developing the sampling frame has been
decided, a number of approaches may be used for sampling
outlets. Some studies employ a convenience method, with
outlets purposively selected given their proximity to urban
or rural centres [18,19]. The most widely used of these
approaches is the WHO/HAI methodology, described in
Additional file 1. While such an approach can have the
benefits of logistical feasibility and low cost, it does not
provide a representative sample and may therefore be sub-
ject to bias. Where a reliable sampling frame has been
obtained, simple random sampling may be used [12], or
the sample may be stratified to ensure that sufficient num-
bers of specific outlet types are captured [14,21]. Alterna-
tively, if a census is conducted to develop the sampling
frame, it may be most efficient to include all censual out-
lets in the sample and complete the full interview at the
time of the census [15,16].
In ACTwatch the aim was to obtain nationally representa-
tive estimates of anti-malarial availability, price and market
share. A stratified random sample of local administrative
areas (e g, wards, communes, parishes) was selected, with
probability proportional to population size (PPS). Stratifica-
tion was based on characteristics likely to affect key out-
comes, for example, urban/rural location, as this was
expected to be associated with differences in the reach of
supply chains, proximity to markets, and intensity of
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demand. Sample size was based on estimating the primary
indicator (proportion of outlets with any artemisinin-based
combination therapy (ACT) in stock among all outlets
stocking anti-malarials) with a specified precision [10], with
sample size calculations refined in later surveys based on
baseline data.
Given that many eligible outlets were unregistered,
mobile, or recently opened, the census approach was
used to develop the sampling frame, supported by the
use of key informant interviews with local officials, local
maps, and lists of registered outlets where available.
Where necessary the data collection team worked with
key informants to produce a sketch map to help assign
data collectors to specific areas or worked with pre-
existing map boundaries to highlight known outlets (see
Figure 1 for an example). In addition, the snowball tech-
nique was used, asking providers interviewed if they
could identify other outlets like their own in the area
where they operated. All outlets visited were screened to
assess eligibility and only those with anti-malarials in
stock or who had stocked them in the previous three
months were invited to participate in the survey.
The ACTwatch experience highlighted two outlet types
that were particularly challenging to identify: itinerant
vendors and community health workers (CHWs). In
keeping with inclusion criteria for other outlet types, it-
inerant vendors (also known as hawkers) were only con-
sidered as having the potential to sell anti-malarials if
they were hawking general household goods, medi-
cines and/or soap. Hawker congregation points were
identified using key informant interviews and hawkers
were approached by interviewers and asked if they
had already participated in the survey to avoid dupli-
cation. For interviewer safety, hawkers were only
approached during daylight hours, given these ven-
dors work late into the night and in potentially un-
safe areas.
Across countries, there is considerable variation in the
names used for CHWs, their roles, funding source, and
registration status. While some CHWs administer anti-
malarials, others work for health interventions unrelated
to malaria; therefore decisions on the possible inclusion
of CHWs in the census must be country specific. When
available, registered listings may be used to locate CHWs
in the field. For example, in some countries there are
links between health posts and CHWs, and updated lists
of CHWs can be provided through the health post provi-
ders. Alternatively there may be an elected CHW repre-
sentative who can be contacted for updated lists. CHWs
can sometimes be identified within a community due to
sign-posts outside their homes.
There is also an important temporal element to sam-
pling, as key outlet characteristics can be expected to
change seasonally in response to fluctuations in disease
burden and accessibility.
Wherever possible ACTwatch surveys were conducted
during the months of peak malaria transmission in each
country, and follow-up surveys repeated during the same
months in subsequent years. Where this was not pos-
sible, surveys were conducted shortly after the peak
transmission season. For example, in Madagascar, sea-
sonal peaks in malaria transmission coincide with the
months when parts of the country are inaccessible due
to heavy flooding and the presence of cyclones, making
Example 1. A hand drawn Cambodian village map that was provided to 
interviewers and used to identify outlets 
Example 2. A preexisting map from Madagascar that was used by 
supervisors during the initial mapping stage to help determine outlet 
locations from key informants.
Figure 1 Examples of maps used during field work to identify boundaries and outlets.
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it difficult to undertake fieldwork which was, therefore,
scheduled just after the months of peak transmission.
Collecting data on medicines
Collecting availability, price and sales volume data
Most medicine surveys include a set of questions on the
characteristics of the outlet and the respondent such as
number of staff, qualifications and provider knowledge.
These questions can be considered relatively straightfor-
ward in comparison with collecting data on medicines.
Collecting survey data on the latter is highly complex
due to the wide variation in products by generic type,
formulation, strength, and pack sizes, and differences in
outlet practices. The first issue to consider is whether
data collected will be restricted to a predetermined
checklist of medicine brands, or more open ended allow-
ing collection of data on a wider range of medicines.
Using a standard predetermined list can facilitate com-
parison across countries and also simplify data collection
as field workers are not required to categorize medicines
during the interview (see for example the WHO/HAI
method described in Additional file 1). The WHO refer-
ence list of essential medicines, for example, can be used
as pre-determined list. Medicines can be pre-coded in
advance if using PDAs or other electronic capture sys-
tems. However, using a more open-ended approach
means data can be collected on all products within a
therapeutic class, thus allowing the calculation of market
share, and highlighting availability of non-recommended
or banned products, whose presence might not have
been expected. An open-ended approach may also be
more flexible where there is a very wide variety of poten-
tial brands and pack sizes.
In collecting price data, clarity is required on whether
data should be collected per pack/tin or per unit (e.g.,
tablet, ampoule). This is important to consider given
that, for example, tablet medicines may be stored in tins
of 100 or 1000 tablets or as pre-packaged therapies of 24
tablets for an adult course. In addition, clear guidance
should be given on the handling of any non-drug costs
that are incurred, for example for registration, consult-
ation, syringes or diagnostic testing, which may only be
required at some outlet types (eg, health facilities but
not drug shops). In including these costs one could be
accused of not comparing like with like, but in excluding
them one may misrepresent the true costs to patients of
visiting alternative outlet types. Ideally they should,
therefore, be collected so that the analysis can be done
with and without such associated costs. Care should also
be taken to collect the retail rather than wholesale sale
price of medicines in outlets that function in both cap-
acities, which may be common for larger pharmacies
that wholesale medicines to smaller pharmacies or drugs
stores. Finally, where exemption mechanisms exist for
certain age groups in, for example public health facilities,
such exemptions can be noted in the comment fields of
the questionnaire. Decisions on how to treat this can
then be dealt with at the analysis stage.
As with price data, clear guidance must be given on
the units for collection of sales volumes (e g, tablets ver-
sus packs versus boxes). The collection of sales volume
data is further complicated by the need to record sales
over a previous time period. One approach is to collect
information from sales records [22], but in practice these
are frequently inaccurate, or in the private sector, not
kept at all, or viewed by sellers as confidential. Alterna-
tively, outlet staff can be asked to recall their sales
volumes during the week or two weeks preceding the
interview [10]. As with all survey recall questions, recall
bias may be a problem if recall is worse of sales con-
ducted further into the past. However, limiting the recall
period to one or two weeks does not capture seasonal
variation of medicine sales (for example, fluctuations
caused by higher or lower malaria transmission seasons)
and longer-term stock-outs. A third approach is to
undertake a retail audit where information is collected
by field teams visiting a panel of outlets at regular inter-
vals [15,20,23,24]. At each visit and in each outlet field
workers measure the stocks of each product and ask
about any volumes added and/or disposed of during the
visit interval, in order to estimate sales. This method
avoids the need to use outlet records or rely on recall of
sales volumes, but still requires recall of wholesale pur-
chases and stock disposed of, and can be challenging
where sellers resist having their stock counted. This
method also imposes considerable time and cost burdens
on the data collection team, and may lead to respondent
fatigue [23].
Generating comparable price and sales volume data: the
adult equivalent treatment dose
A challenge in conducting medicine outlet surveys is the
measurement of price and sales volume in a standar-
dized way across drug types because of the considerable
variation in strength, pack size, formulation and dose
length across products, even within a given therapeutic
class. Moreover, while some drugs are pre-packed for
specific age groups, others are sold loose, eg, from pots
of 500 or 1,000 tablets. For chronic conditions, measures
such as the “defined daily dose” have been used as the unit
of comparison [25], but this is inappropriate for short-term
treatments where treatment duration varies [26]. For
example, it would not be appropriate to compare data for a
daily dose of the anti-malarial sulphadoxine-pyrimethamine
with quinine, given that the former is a one-day treatment
regimen and the latter is seven days. An alternative
used for anti-malarials is the adult equivalent treatment
dose (AETD) [5,10,24,26,27]. One AETD is defined as the
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number of milligrams (mg) of an anti-malarial ingredient
needed to treat a 60 kg adult. Under ACTwatch, for
each anti-malarial category, the number of mg in one
AETD is defined as that recommended in the treatment
guidelines for uncomplicated malaria in areas of low drug
resistance issued by the WHO [10]). Where WHO treat-
ment guidelines do not exist, an AETD is based on peer
reviewed research, or where this is not available, on the
product manufacturer’s recommended treatment course. In
the case of ACT, with two or more active anti-malarial
ingredients packaged together, the strength of the artemisi-
nin-based component is used as the basis for the AETD
calculations.
There are some cases when one AETD equates precisely
to a ‘real’ product. One example is the CoartemW 24 tablet
package. In total the 24 tablets contain 480 mg artemether,
which is the amount of artemether that defines one AETD
(Table 1). By extension, a 12-tablet pack equals 0.5 AETD,
and a 6-tablet pack equals 0.25 AETD.
The minimum attributes on each product needed to
conduct AETD calculations are show in Table 2. It may
also be useful to collect additional attributes such as
brand name, manufacturer and country of manufacture
to assist with data cleaning, assess market share by
manufacturer and country of origin, and allow drugs to
be classified into categories such as WHO-approved or
nationally registered.
It should be noted that where many customers are
children and where purchase of under-doses is common,
the estimated number of AETDs sold will be lower than
the actual number of sales made. Similarly, the average
price per AETD will be higher than the average price paid
per customer. Furthermore the AETD approach can mask
differences in costs between adult and paediatric packs as all
products within a generic category are generally combined
to estimate price per AETD. While an advantage of the
AETD approach is that it allows comparison of prices across
formulations (tablets versus syrups versus injectables), care
should be taken in presenting average price data for several
formulations combined as the price distributions for non-
tablet formulations tend to be different from those for
tablets, with much higher medians, implying that it could be
misleading to use one measure of central tendency across
different formulations [10]. The AETD approach could be
extended to calculate price and sales volumes for other med-
icines, though it is less appropriate for drugs that are not
taken in a course of a specific length, e g, paracetamol.
Ensuring high quality data collection in a medicine outlet
survey
Key quality assurance steps common to all research
studies include questionnaire design and field worker
training. An additional area that may require particular
attention for medicine outlet surveys is identifying all
relevant medicines in an outlet.
Questionnaire design
Good questionnaire design can help greatly to reduce
errors during fieldwork, particularly in the design of
“audit sheets” for collection of data on products stocked.
ACTwatch audit sheets represent a useful resource for
future surveys given that they have been refined based
on the experience of numerous survey rounds [28]. They
have the following key features:
Given the different data required, separate audit sheets
are use for “tablet, suppository and granule products”,
and syrup and injectable or “non-tablet” products
(see examples in Figures 2 and 3);
Audit sheets are designed to allow entry of
combination medicines with up to three active
ingredients;
A comments box is provided to allow data collectors to
note anything unusual about the product which may
affect the calculation of AETDs (e g, if an anti-malarial
is packaged with non-anti-malarial and a correction to
the recorded pack size required during analysis. In
some instances Fansidar (SP) is packaged with
Table 1 Common adult equivalent treatment dose (AETD) reference values for anti-malarial active ingredients
Generic name Ingredient used for
AETD calculation
mg dose required
for 1 AETD
Source
Quinine Quinine 10408 (as base1) WHO Model Formulary, 2008
Sulphadoxine-
pyrimethamine
Sulphadoxine 1500 WHO Model Formulary, 2008
Artemether-
lumefantrine
Artemether 480 WHO Model Formulary, 2008
Artesunate-
Amodiaquine
Artesunate 600 Manufacturer recommendations (also quoted in the WHO Guidelines for the
treatment of malaria, 2nd edition, 2010)
1 Due to the pharmacodynamic properties of active ingredients, some medicines are manufactured as salts in order to improve the taste or slow down the
absorption of the active ingredient. Care needs to be taken with such products as the strength in salt form will be greater than the base strength of the active
ingredient. For example, 10,408 mg of quinine base corresponds to 12,600 mg of quinine sulphate, a common salt used in the presentation of quinine tablets.
Source: ACTwatch.
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paracetamol and interviewers should record the
number of tablets of each product in the comments;
The sheets allow flexibility on the units for which
prices and volumes are recorded, avoiding the need for
data collectors to perform calculations themselves;
Additional audit sheets can be added if required in
well-stocked outlets;
Each product and page has a serial number and the
number of audit sheets completed/medicines are
recorded on the main body of the questionnaire to
ensure that all are present during data entry.
Field worker training
For a medicine outlet survey, ensuring quality of training
and thorough comprehension by field workers can be
more challenging than for other surveys because of the
detailed medicine-related data collected. However, in
common with all surveys, good training is the key to
success. ACTwatch have developed a seven-day outlet
survey training curriculum that details how to complete
each section of the questionnaire, as well as covering
conducting a census and good interviewing practice, and
including practice in the field (Additional file 2). A full
Table 2 Medicine attributes essential for the correct calculations of adult equivalent treatment doses (AETDs)
Attribute Role in AETD calculation Notes
Generic name Used to define the number of milligrams of active ingredient
required for 1 AETD.
Also enables classification of medicines by different classes
for analysis (e g, monotherapies vs combination therapies)
Strength of
active ingrediets
Taken together, strength and pack size are used to calculate how
many milligrams of active ingredient are present in the medicine
package.
Also enables classification of medicines, most notably used
to flag first-line treatments, which are defined in terms of
generic name and strength.
Pack size Requires different definitions for tablet and non-tablet
medicines.
Is product a
fixed dose
combination?
One of these two attributes is required in order to establish the
ratio of tablets in co-blistered medicines. This information is then
used to modify the pack size value in the AETD calculation, if
necessary.
Brand name
Source: ACTwatch.
Design elements common to both sheets include space 
for one strength response matched to each active 
ingredient.
Spaces for up 
to three active 
ingredients to 
be recorded 
for any one 
product.
Consider the TSG and NT cells for volumes. 
Sales volumes for loose tablets are usually 
given in terms of tablets, whilst volumes for 
packages are usually given in terms of packs. 
The TSG sheet thus includes spaces for both, 
allowing the field worker to be led by the 
respondent and removing the need for 
calculations. By contrast, the corresponding 
NT cell only requires 1 option.
The cells used to collect price information are able to 
capture responses that range from 1 tablet to 99 tablets. 
This allows the interviewer to record the price as specified 
by the respondent, without needing to convert to a common 
number of tablets (e.g. loose quinine prices can be recorded 
per tablet, per 10 tablets, or per 42 tablets without the need 
for calculation).
A question is included to determine if a 
medicine is a fixed-dose combination (i.e. has 
2 or more active ingredients combined in a 
single tablet, suppository or granule pack).
Ingredient strengths may be presented as base or in salt form on medicine packaging. A 
question is included to identify strengths presented for salts, so that they can be 
correctly accounted for during analysis.
Figure 2 Examples of the tablet, suppository and granule (TSG) audit sheets from the ACTwatch questionnaire.
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facilitator curriculum is provided, including presentation
slides for each topic and advice on points to be made
with each slide. The sessions are highly interactive, in-
volving numerous practical exercises and games to
emphasize key concepts, and a series of interviewer tests
to assess knowledge throughout the training period.
Repetition is built into the schedule, with earlier topics
re-examined and tested as new ones are introduced.
These training materials, as well as standard operating
procedures to help prepare for the training and field-
work, are available on the web [28]. Training materials
can be used with only minor country specific adapta-
tions, for example, to include locally common brands
and outlet types, and have been adapted for other anti-
malarial surveys.
Lessons learned from successive rounds of ACTwatch
surveys have fed into the training materials and in par-
ticular the approach taken to introduce certain topics.
For example, the authors have found it useful to intro-
duce the topics of generic names and brand names with
reference to everyday items such as milk or bread; and
when discussing the strength of liquid formulations it
has been helpful to have a practical demonstration of
dissolution in class. Prior to training, a large variety of
medicines available in the country are purchased for
presentation during training sessions and use in exer-
cises and tests, representing the broadest possible range
of dosage forms, brands, generics and pack sizes. Having
access to a wide range of examples not only allows the
trainers to present many different scenarios during the
training sessions, but rotating medicines between field
workers during tests helps to mitigate against people
‘remembering’ the correct answers for a given product.
Given the complexity of the training programme, ex-
perience shows that despite intensive training not all
field workers are able to grasp these issues. It is there-
fore advisable to over-recruit trainees, to ensure suffi-
cient numbers are eligible for the fieldwork.
ACTwatch has also developed additional training
materials for team supervisors and quality controllers
who conduct back-checks to outlets already visited by
data collectors to check on performance.
Identifying all relevant drugs in an outlet
For a study employing a ‘full audit’ approach for a given
medicine or disease class, a major challenge is ensuring
that all relevant products are audited. Without due care
it is common to find that products are missed because
they are forgotten, sellers do not realize that they are
relevant, sellers wish to conceal them as they believe
they are not permitted to stock them, or interviewers ig-
nore them to reduce the data collection workload. Sev-
eral strategies can be employed to minimize this.
Strength, dosage form, pack size and amount 
sold collect the same information on each sheet, 
but are specified differently for tablets and non-
tablets to assist the field workers to collect 
accurate information. Questions specify that this 
information is collected in reference to how the 
package is sold or distributed to the consumer.
Design elements common to both sheets includes spaces 
for brand name, manufacturer, country of manufacture, 
retail selling price and comments. As much white space 
as possible is given to the brand name and manufacturer 
cells, as these are key attributes that are not only used to 
classify products but also to verify other entries in an 
audit row.
Other indicators can be included such as measures 
of expiry, stock outs, or wholesale purchase price.
Audited medicines are 
assigned a running product 
number within the TSG and 
NT audit sheets. These are 
used for cross-checking 
during data entry verification 
and data cleaning.
Audit sheet pages contain a space for a running 
total number of sheets completed at the base.  
This is a simple but useful data quality tool for 
checking completed questionnaires still contain 
all their pages prior to data entry.
Active ingredients 
and their combined 
generic product, 
and country of 
manufacture are 
coded prior to data 
entry, reducing the 
burden on data 
entry. 
Figure 3 Examples of the non-tablet (NT) audit sheets from the ACTwatch questionnaire.
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Firstly, the information provided during consent pro-
cedures should make it explicitly clear that the interview
is not an inspection and that the data gathered will be
confidential in order to encourage full disclosure. Sec-
ondly, it is helpful to include a set of prompts in the
questionnaire around specific generic types and formula-
tions to reinforce the need to audit all medicines, and
not just the most common ones. This can be comple-
mented by a photo book of different types of medicines,
to remind the seller of any other drugs that might be in
stock. Data collectors should also be trained to recognize
relevant medicines so they can (subtly) scan the pro-
ducts on display in outlets.
Quality control checks
Field supervisors should review all completed question-
naires for completeness. Supervisors should also note
challenges with specific questions, which interviews may
commonly skip or mark incorrectly. In addition, back-
check visits to outlets should be conducted by separate
quality control staff to check that outlets were indeed
visited and to counter any incentives for data collectors
to try to reduce data collection time by for example
skipping certain products in the audit. With a well-
designed back check questionnaire it is not necessary for
quality control staff to repeat the whole questionnaire,
but rather to collect data on specific key variables. This
can also provide an opportunity to ask questions about
the interviewer’s conduct and politeness. General obser-
vation by supervisors is also key to monitor fieldworkers
adherence to fieldwork practices including consent pro-
cedures, conducting the census, and use of data collec-
tion materials.
Conclusion
This paper has provided guidance on key steps in con-
ducting a medicine outlet survey in a developing country
context, drawing on the ACTwatch project and other
studies. While the basic principles of good survey design
and implementation are highly relevant, there are also a
set of specific issues that should be considered when
conducting an outlet survey. These include careful con-
sideration of: inclusion criteria by outlet type; methods
for developing a reliable sampling frame and for select-
ing outlets; specific issues in the collection of data on
medicines; and approaches for generating comparable
price and sales volume data across products. Given the
resulting complexity of survey methods it is essential
that this is complemented with a well-designed ques-
tionnaire, rigorous field worker training and strong qual-
ity control procedures. The survey materials developed
by ACTwatch provide a helpful resource for future stud-
ies on anti-malarials and markets for medicines in
general.
Additional files
Additional file 1: Summary of the WHO/HAI approach to outlet
sampling. The World Health Organization (WHO)/Health Action
International (HAI) methodology for sampling medicine outlets has been
standardized and applied across many countries [29,30]. The surveys aim
to monitor to the price, availability and affordability (price) of medicines.
The guidelines recommend selecting outlets in six geographic areas
across four sectors, namely: public sector hospitals and clinics, the formal
commercial sector, unlicensed or informal commercial sector, and not-
for-profit organizations (where present). Survey areas include the main
urban centre plus three areas randomly selected from those that can be
reached within a day’s travel from the main urban centre. In each survey
area, the main public hospital, plus four randomly selected public
medicine outlets reachable within 4 hours’ travel from the main hospital
define the public sector facility sample. The private sector and other
sector samples are identified by selecting one medicine outlet in each
sector that is geographically closest to each public outlet. This results in a
basic sample size of up to 120 outlets [29]. This sampling strategy has
been used to provide routine monitoring data for essential medicines
across a number of countries [19,31-33]. The WHO/HAI method restricts
inclusion to a maximum of 50 medicines. These include 14 global and 16
regional essential medicines, pre-determined by WHO/HAI to enable
cross-country comparisons, and 20 supplementary essential medicines
identified at the country level. For each of the 50 generic medicines
selected, two products are then surveyed: i) the originator brand (using
the same pack size and strength in each outlet) and ii) the lowest-priced
generic product that contains the same active ingredient as the
originator brand. The HAI/WHO method is a highly feasible approach to
implement and can be notably less expensive than surveys that
implement a census approach. The purposeful selection of sampling
areas and outlets however limits the ability to extrapolate findings to the
national level, and the relatively small sample size means the method
does not have the power to detect small but potentially important
differences in indicators. The HAI method has been adapted to overcome
this challenge by identifying all private registered and unregistered
sources of anti-malarial drugs within three hours’ drive from each public
health facility using lists of outlets and key informants, and randomly
sampling five outlets of each type [17]. However, the restriction to five
outlets per area from each sector risks missing differences between
different types of informal commercial outlets in countries that support a
diverse informal medicine market. Additional resources, including study
design templates and analysis folder in Excel can be found on the HAI
website.
Additional file 2: Training topics for ACTwatch outlet surveys.
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